GEN-MKT-18-7897-A
Apr 28, 2026 | Biopharma, BioPhase 8800 system, Blogs | 0 comments
CE‑SDS remains a cornerstone assay for characterizing fragmentation, aggregation, and product‑related impurities in therapeutic proteins. UV detection has been the long‑standing standard. However, it frequently struggles with baseline noise, limited sensitivity for minor fragments, and subjective integration.
Native fluorescence detection (NFD) strengthens CE‑SDS performance by improving both detection sensitivity and interpretability.
High sensitivity without labeling
NFD leverages intrinsic tryptophan fluorescence to detect proteins label‑free, avoiding the variability and workflow burden of dye‑labeling steps.
Technical note data show:
For scientists managing stability programs or performing forced degradation studies, this sensitivity can reveal early‑stage degradation signatures that UV cannot reliably resolve.
Clearer, more stable baselines for better integration
Typical UV electropherograms show baseline drifting due to buffer absorbance and gel heterogeneity.
The NFD baseline, however, is consistently flat, improving:
These benefits reduce manual reprocessing and strengthen data defensibility across development stages.
Multi-capillary throughput for faster studies
The BioPhase 8800 system processes 8 samples in parallel, expanding CE‑SDS throughput without requiring additional instruments or longer sequences.
High‑throughput CE‑SDS paired with NFD’s sensitivity provides a strong foundation for data‑driven therapeutic development.
A balanced upgrade path from UV and LIF
NFD complements existing detection modes:
This offers scientists flexibility while building long‑term method robustness.
Explore the CE‑SDS NFD data
For deeper review, check out the resources in our NFD solutions hub >
As therapeutic pipelines continue to diversify, bioanalysis is being asked to do more than ever before. From small molecules to complex biologics, today’s scientists must generate high‑quality, reliable data across a growing range of molecule types and workflows, often under increasing time pressure.
Regulated laboratories are evolving faster than ever. New analytical modalities, higher sample throughput, increasing regulatory scrutiny, and leaner teams are reshaping how work gets done. At the same time, expectations for data integrity, standardization, and operational efficiency continue to increase complexity and/or scope. In this environment, LC-MS software is no longer simply an instrument control platform—it has become a critical part of a laboratory’s quality management system. The question is no longer whether your lab has changed, but whether your software has evolved to support the way regulated labs operate today, and if they are ready and able to meet the demands, they will face tomorrow.
Analyst software has long been a trusted foundation in regulated LC-MS laboratories—and for many, it still performs reliably today. But regulated environments are evolving faster than ever. As labs transition to Windows 11, strengthen cybersecurity policies, modernize IT infrastructure, and prepare for future compliance expectations, software decisions are no longer just about what works today—they’re about managing tomorrow’s risk. Analyst will not be supported on Windows 11. While some labs may continue operating in unsupported environments temporarily, the bigger question is: when that risk becomes reality, will your lab be reacting under pressure—or executing a planned mitigation strategy with confidence?
Posted by
You must be logged in to post a comment.
Share this post with your network